Why Halozyme Therapeutics, Inc. Stock Jumped 21.2% in September


Image source: Getty Images.

Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) a biotechnology company focused on enhancing drug delivery, rose 21.2% in September, according to data from S&P Global Market Intelligence. The stock tanked to begin the year, but following a handful of conference presentations last month, it appears back in favor.

Continue reading

view Fool